News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,905 Results
Type
Article (44379)
Company Profile (326)
Press Release (672200)
Multimedia
Podcasts (82)
Webinars (12)
Section
Business (207935)
Career Advice (2024)
Deals (35954)
Drug Delivery (110)
Drug Development (83994)
Employer Resources (174)
FDA (16682)
Job Trends (15117)
News (352703)
Policy (33284)
Tag
Academia (2686)
Academic (1)
Accelerated approval (6)
Adcomms (26)
Allergies (88)
Alliances (50790)
ALS (93)
Alzheimer's disease (1442)
Antibody-drug conjugate (ADC) (144)
Approvals (16663)
Artificial intelligence (270)
Autoimmune disease (26)
Automation (16)
Bankruptcy (365)
Best Places to Work (11852)
BIOSECURE Act (22)
Biosimilars (110)
Biotechnology (235)
Bladder cancer (85)
Brain cancer (31)
Breast cancer (296)
Cancer (2382)
Cardiovascular disease (191)
Career advice (1691)
Career pathing (30)
CAR-T (173)
Cell therapy (482)
Cervical cancer (20)
Clinical research (68186)
Collaboration (893)
Company closure (1)
Compensation (549)
Complete response letters (27)
COVID-19 (2671)
CRISPR (47)
C-suite (254)
Cystic fibrosis (106)
Data (2244)
Decentralized trials (2)
Denatured (23)
Depression (50)
Diabetes (284)
Diagnostics (6495)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (108)
Drug shortages (28)
Duchenne muscular dystrophy (100)
Earnings (87555)
Editorial (42)
Employer branding (21)
Employer resources (148)
Events (115444)
Executive appointments (742)
FDA (17969)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (785)
Gene editing (116)
Generative AI (21)
Gene therapy (354)
GLP-1 (779)
Government (4535)
Grass and pollen (4)
Guidances (67)
Healthcare (19325)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (132)
Indications (30)
Infectious disease (2816)
Inflammatory bowel disease (145)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (99)
Interviews (313)
IPO (16749)
IRA (42)
Job creations (3695)
Job search strategy (1434)
Kidney cancer (11)
Labor market (38)
Layoffs (501)
Leadership (18)
Legal (8014)
Liver cancer (78)
Lung cancer (338)
Lymphoma (159)
Machine learning (7)
Management (58)
Manufacturing (324)
MASH (72)
Medical device (13621)
Medtech (13626)
Mergers & acquisitions (19759)
Metabolic disorders (739)
Multiple sclerosis (81)
NASH (18)
Neurodegenerative disease (105)
Neuropsychiatric disorders (32)
Neuroscience (2012)
NextGen: Class of 2025 (6717)
Non-profit (4581)
Now hiring (39)
Obesity (394)
Opinion (221)
Ovarian cancer (77)
Pain (95)
Pancreatic cancer (84)
Parkinson's disease (157)
Partnered (21)
Patents (241)
Patient recruitment (115)
Peanut (48)
People (58386)
Pharmaceutical (76)
Pharmacy benefit managers (18)
Phase I (21284)
Phase II (29976)
Phase III (22388)
Pipeline (1238)
Policy (150)
Postmarket research (2721)
Preclinical (9076)
Press Release (69)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (263)
Rare diseases (416)
Real estate (6014)
Recruiting (67)
Regulatory (22908)
Reports (46)
Research institute (2428)
Resumes & cover letters (352)
Rett syndrome (5)
RNA editing (5)
RSV (43)
Schizophrenia (75)
Series A (138)
Series B (89)
Service/supplier (12)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (155)
Sponsored (30)
Startups (3710)
State (2)
Stomach cancer (16)
Supply chain (68)
Tariffs (41)
The Weekly (57)
Vaccines (724)
Venture capitalists (41)
Weight loss (268)
Women's health (37)
Worklife (17)
Date
Today (158)
Last 7 days (954)
Last 30 days (2716)
Last 365 days (33827)
2025 (11112)
2024 (36307)
2023 (41053)
2022 (52296)
2021 (56827)
2020 (55098)
2019 (47636)
2018 (35957)
2017 (33035)
2016 (32438)
2015 (38445)
2014 (32164)
2013 (27177)
2012 (29331)
2011 (30045)
2010 (28196)
Location
Africa (746)
Alabama (53)
Alaska (7)
Arizona (237)
Arkansas (13)
Asia (39223)
Australia (6492)
California (6250)
Canada (2032)
China (551)
Colorado (273)
Connecticut (282)
Delaware (150)
Europe (86337)
Florida (933)
Georgia (215)
Idaho (58)
Illinois (553)
India (26)
Indiana (314)
Iowa (11)
Japan (167)
Kansas (107)
Kentucky (25)
Louisiana (10)
Maine (62)
Maryland (911)
Massachusetts (4739)
Michigan (220)
Minnesota (396)
Mississippi (2)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (63)
New Hampshire (68)
New Jersey (1760)
New Mexico (30)
New York (1780)
North Carolina (1040)
North Dakota (9)
Northern California (2716)
Ohio (207)
Oklahoma (15)
Oregon (35)
Pennsylvania (1402)
Puerto Rico (12)
Rhode Island (33)
South America (1121)
South Carolina (23)
South Dakota (1)
Southern California (2329)
Tennessee (103)
Texas (922)
United States (23719)
Utah (183)
Virginia (147)
Washington D.C. (65)
Washington State (563)
West Virginia (3)
Wisconsin (55)
716,905 Results for "biorestorative therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update
March 28, 2025
·
7 min read
Pharm Country
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York.
June 4, 2024
·
3 min read
Press Releases
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025
March 20, 2025
·
4 min read
Business
BioRestorative Therapies Provides First Quarter 2024 Business Update
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today provided an update on its business.
May 14, 2024
·
6 min read
Pharm Country
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
BioRestorative Therapies, Inc. reported that it has had substantive discussions with an undisclosed commercial stage regenerative medicine company with regard to a license of BioRestorative’s allogeneic, off-the-shelf ThermoStem® metabolic intellectual property.
June 13, 2024
·
5 min read
Pharm Country
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
BioRestorative Therapies, Inc . is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135 related to the Company’s allogeneic, off-the-shelf ThermoStem® platform.
June 27, 2024
·
6 min read
Press Releases
BioRestorative to Provide a Positive FDA Update on Clinical Pipeline
February 26, 2025
·
4 min read
Drug Development
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
BioRestorative Therapies, Inc., a clinical stage company focused on stem cell-based therapies, announced its development of a novel exosome-based biologic program targeting obesity.
May 8, 2024
·
5 min read
Pharm Country
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 at the Ritz Carlton, Laguna Niguel in Dana Point, California
March 11, 2024
·
3 min read
Deals
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
BioRestorative Therapies, Inc. announced that it has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).
June 17, 2024
·
4 min read
1 of 71,691
Next
